Heron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares
SAN DIEGO--(BUSINESS WIRE)--Jan. 31, 2017--
Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology
company focused on developing novel best-in-class treatment solutions to
address some of the biggest unmet patient needs, today announced that
the underwriters for its recent public offering of common stock have
exercised in full their option to purchase an additional 1,845,000
shares of its common stock, which sale is expected to close on February
3, 2017, subject to customary closing conditions. Total net proceeds of
the public offering, including the underwriters’ option to purchase
additional shares, are expected to be approximately $163.7 million,
after deducting expenses and underwriting discounts and commissions.
BofA Merrill Lynch, Cowen and Company, LLC and Leerink Partners LLC are
acting as joint book-running managers for the offering. Cantor
Fitzgerald & Co. and JMP Securities LLC are acting as lead managers, and
Noble Capital Markets, LifeSci Capital, Aegis Capital Corp and Lake
Street Capital Markets are acting as co-managers for the offering.
The securities described above are being offered pursuant to a shelf
registration statement (File No. 333-212784), which became effective
automatically on July 29, 2016. A final prospectus supplement relating
to and describing the terms of the offering was filed with the SEC on
January 19, 2017. The securities described above have not been qualified
under any state blue sky laws. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any state
or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities
laws of any such state or other jurisdiction. The offering can be made
only by means of a prospectus, copies of which may be obtained at the
United States Securities and Exchange Commission’s website at www.sec.gov,
or by request at BofA Merrill Lynch, NC1-004-03-43, 200 North College
Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus
Department or by email at email@example.com;
Cowen and Company, LLC, c/o Broadridge Financial Services, Attention:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by
telephone at (631) 274-2806 or by fax at (631) 254-7140; and Leerink
Partners LLC, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, by telephone at (800) 808-7525 ext. 6142 or by
email at firstname.lastname@example.org.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170131005502/en/
Source: Heron Therapeutics, Inc.
Investor Relations Contact:
Heron Therapeutics, Inc.
Senior Vice President, General Counsel,
Business Development & Corporate Secretary
Heron Therapeutics, Inc.
Senior Vice President, General Counsel, Business
Development & Corporate Secretary